This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gentris Corporation Announces Changes To Board Of Directors

Related Links:  


"As Gentris enters its second decade, the Company is fortunate to have experienced executives like Dr. David Drutz and Tim Gupton serving on the Board of Directors," said Rick Williams, CEO of Gentris Corporation. "Dr. Drutz and Mr. Gupton have been involved in many facets of the biopharma industry.  They understand how to guide a senior management team and its advisors to create scientific innovation and generate high-growth commercial results."

"Pharmacogenomics is directed to understanding how drugs interact with our genetic makeup," said Dr. David Drutz, chair of the Gentris board of directors.  "As such, pharmacogenomics enables therapeutic agents to be directed toward those individuals most likely to have a favorable clinical response and away from those most likely to suffer adverse effects.  Pharmacogenomics serves as a centerpiece for the future of drug development in the pharmaceutical and biotechnology industries.  I am delighted to be associated in such an important way with a well-established company that is working at the cutting edge in this exciting endeavor."

"As an investor from Research Triangle Ventures," Tim Gupton said, "I've been associated with Gentris since its inception.  Gentris has always been driven by excellent science and quality standards and has been a leader in helping the pharmaceutical industry to use genetic data to differentiate their drug candidates.  With clinical biomarkers becoming an expectation for drug development, I'm confident that Gentris will remain a leader in the rapidly growing field of personalized medicine."

About Gentris Corporation:

Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.  In the past year, Gentris significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.

The Gentris team has collaborated with sponsors to incorporate pharmacogenomics into more than five hundred clinical trials around the world.  Its scientists routinely design complex de novo genomic assays.  The Company's Integrated BioRepository Solutions business unit manages study-site logistics, conduct genomic assessments, and store patient biospecimens.

For additional information, please visit or call 919.653.5534.


Gentris Corporation, Genomics, Clinical Genomics, Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Individualized Medicine, Biomarkers, Genomic Assays, Genomic Methods, Hepatitis, Oncology, Cancer, Immunology, Biobanking, Biorepository, Biospecimens, Integrated BioRepository Solutions.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs